Berberine is among the most-researched metabolic actives of the past decade, with a broad literature base on glucose balance and lipid profile. The molecule's practical limit is equally clear: it is water-insoluble, poorly absorbed, and subject to P-glycoprotein efflux. Metaberine® was designed to overcome that limit with the BioSOLVE® platform.
The BioSOLVE® matrix renders berberine water-dispersible, delivering approximately 4× bioavailability versus standard market berberine HCl.[1] The same plasma exposure can therefore be achieved at a lower label dose ; meaning smaller dosage units and a wider gastrointestinal tolerance window.
Formulations targeting the glucose-balance research area
Lipid-profile support complexes
Weight-management and metabolic-syndrome support lines
Combinations with chromium, alpha-lipoic acid, cinnamon extract
Low-dose-unit capsule/tablet design
n=36
Randomised, double-blind, crossover RCT
200mg
Daily clinical dose · 14 days